AuthorisedTherapeutic use (Phase IV)Interventional

Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE

The PEACE study is investigating the best way to treat small blood clots in the lungs of people with cancer. These clots are often found by chance during scans for their cancer. The study is comparing several common blood-thinning medicines, such as Edoxaban, Dalteparin, and Apixaban, to see which ones work best. Researchers are looking at important things like preventing more clots, avoiding serious bleeding, and how these treatments affect a patient's overall health and quality of life. The goal is to provide clearer guidance for doctors on treating this specific but often-seen problem in cancer patients, making sure they receive the safest and most effective care.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Region Hovedstaden

Enrolment target

234

Start

04 Jun 2026

Incidental Subsegmental Pulmonary Embolism in cancer patients

What is this study about?

The PEACE study is looking into a common but tricky situation for cancer patients. Sometimes, during a scan for their cancer, doctors find very small blood clots in the lungs. These are called 'incidental subsegmental pulmonary emboli' and they're usually found by chance because they don't always cause noticeable symptoms.

Because these clots are small, doctors aren't always sure what the best way to treat them is. Should they be treated with strong blood thinners, or is it better to just keep an eye on them? This study aims to answer that question by comparing several different blood-thinning medications that are already used in healthcare. The researchers want to understand which treatments are most effective at preventing these clots from becoming bigger or causing more serious health problems, while also making sure the treatment itself doesn't cause too many side effects, like bleeding.

To do this, the study will carefully track patients taking these different medicines. They will look at important health outcomes like whether patients develop new clots, experience serious bleeding, or how the treatment affects their overall health and quality of life. The information gathered from this study will help doctors make better decisions about how to care for cancer patients with these small lung clots, ensuring they get the most appropriate and safest treatment.

Key takeaways

The PEACE study is for cancer patients with small, unexpected blood clots in their lungs.
It compares different blood-thinning medicines to find the safest and most effective treatment.
Researchers will monitor for new clots, bleeding, and how treatment affects quality of life.
The study aims to help doctors make better treatment choices for cancer patients with these clots.
Participation involves taking medication, regular check-ups, and completing questionnaires.

Who may be eligible?

To join the PEACE study, you would generally need to be an adult, aged 18 or over. This study is open to both men and women.

The main requirement for being considered for this study is that you have cancer and that doctors have recently found small, incidental blood clots in your lungs during a scan. These clots are typically discovered when you're being checked for your cancer, rather than because you developed new symptoms of a clot.

There might be other specific health conditions or medications that would mean you couldn't take part, to ensure the study is safe for everyone involved and that the results are clear. Your doctor would be able to explain all the detailed criteria.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you currently have cancer?
Have doctors recently found a small blood clot (or clots) in your lungs during a scan?
Are you able to attend regular medical appointments and follow a treatment plan?
Are you able to complete questionnaires about your health and quality of life?

Answer every question to see your result.

What does participation involve?

If you decide to take part in the PEACE study, you would be given one of several blood-thinning medications. These are medicines that are already approved for use and commonly prescribed. You would follow a treatment plan for a certain period, which your study team will explain in detail.

Throughout the study, you would have regular visits with your healthcare team. These visits would involve assessments to see how you're responding to the treatment, if the clots are changing, and to check for any side effects, particularly bleeding. You would also be asked to complete questionnaires about your quality of life, which helps researchers understand how the treatment affects your daily living.

The study team will monitor your health closely, and you would need to attend all scheduled appointments. The total duration of your participation, including follow-up, would be clearly explained to you before you agree to join.

Potential risks and benefits

Taking part in the PEACE study might offer the benefit of receiving close medical monitoring for your lung clots and potentially finding the most effective treatment for your specific situation. However, like all medications, blood thinners carry risks, primarily bleeding. This bleeding can range from minor to more serious. The study team will carefully monitor you for these risks and promptly address any concerns. You are always free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Denmark

Common questions

What are 'incidental subsegmental pulmonary emboli'?

These are small blood clots found in the tiny branches of your lung arteries. 'Incidental' means they were found by chance during a scan for your cancer, not because you had symptoms.

What kind of medicines are being tested?

The study is comparing different blood-thinning medicines, like Edoxaban and Dalteparin. These are already used to prevent and treat blood clots.

Why is this study important for cancer patients?

Cancer patients have a higher risk of blood clots. This study helps doctors understand the best way to treat these small lung clots specifically in cancer patients, balancing the benefits of preventing bigger clots with the risk of bleeding from blood thinners.

Will I know which medicine I'm getting?

The study team will explain if you will know which specific medicine you are receiving or if it will be chosen randomly, like flipping a coin for two choices, to help get the best scientific results.

How will the study affect my cancer treatment?

One of the things the study looks at is whether the treatments for lung clots affect your ongoing cancer treatment. The goal is to ensure both are managed together safely and effectively.